Multiple myeloma is diagnosed in approximately 588,161 people per year worldwide and in an estimated 34,920 people in US. Multiple myeloma accounts for almost 2% of cancer diagnosed and 10% of all hematological malignancies. The 5-year survival has been increased over the past decades with the introduction of new targeted therapies and transplant techniques. Immunohistochemistry plays a very important role in making diagnosis and differential diagnosis, classifying multiple myeloma, and making therapeutic decisions.

CD138: https://bit.ly/CD138

CD56: https://bit.ly/CD56NCAM-1

Kappa: https://bit.ly/KappaLightChain

Lambda: https://bit.ly/LambdaLightChain

Order Now: https://bit.ly/DBS-Distributors